Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Jul.25.2024
Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development
INTER-TABAC in Dortmund, Germany, one of the largest tobacco expos globally, opens September 19, shaping 2024's industry outlook.

On September 19, INTER-TABAC will open in Dortmund, Germany (also known as "the Dortmund tobacco show"). As one of the largest tobacco exhibitions in Europe and even globally, the Dortmund tobacco show is also set to become one of the most anticipated events in the global tobacco industry in the second half of 2024.

 

In their multiple collaborations with the Dortmund Tobacco Fair, 2FIRSTS has served as the official media partner twice. This year, 2FIRSTS will continue their partnership with the Dortmund Tobacco Fair for the third time as the official media partner. They will provide full coverage of the event from various angles, presenting the latest information to the industry.

 

Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development
2FIRSTS has repeatedly reported on the Dortmund exhibition dynamics in a comprehensive and multi-dimensional manner as an official cooperating media outlet. | Image Source: 2FIRSTS

 

In order to support the growth of e-cigarette brands, promote the high-quality development of overseas brands, and deepen the close connection between the Chinese supply chain and global markets, 2FIRSTS has developed a comprehensive corporate communication service plan based on its strong exhibition reporting experience and professional media influence to provide cost-effective communication solutions for businesses.

 

This program is customized specifically for e-cigarette companies, integrating the authoritative expertise in the e-cigarette industry of 2FIRSTS with its significant traffic advantages on both the English website (2firsts.com) and Chinese website (2firsts.cn), along with precise social media coverage. Additionally, 2FIRSTS provides full-stage services tailored to the communication needs of enterprises of different sizes, from pre-show preparation to on-site display, and post-show follow-up, aiming to enhance the brand's influence in the global e-cigarette industry.

 

Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development
During the exhibition, 2FIRSTS conducted in-depth interviews with some key exhibiting companies, aiming to fully understand the current development status and future trends of these companies. | Image source: 2FIRSTS

 

Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development
On site, 2FIRSTS keenly captures the details of the exhibition, deeply analyzes the on-site situation, and brings readers the freshest first-hand information. | Image source: 2FIRSTS

 

The program will officially launch on July 25th. For more details, please feel free to add the 2FIRSTS customer service WeChat for consultation, or directly send an email to info@2firsts.com. 2FIRSTS will provide you with the most comprehensive answers.

 

CONTACT INFORMATION:

Countdown to INTER-TABAC: 2FIRSTS Unveils Media Services Plan to Empower High-Quality Business Development

 

In addition, during the exhibition, 2FIRSTS will once again dispatch a professional reporting team to go deep into the field, engaging in in-depth communication with major exhibiting brands and foreign distributors. From an objective and professional perspective, we will bring the latest firsthand information and profound industry insights to global readers. Stay tuned.

 


 

About 2FIRSTS

 

2FIRSTS is a company that specializes in creating innovative and unique products and services.

 

2FIRSTS is a leading global vaping industry media and consultancy, providing the industry's latest news, data, and insights to regulators, entrepreneurs, researchers, media, and other stakeholders worldwide. Every day, more than 10,000 global visitors log on to 2FIRSTS' English (www.2firsts.com), Chinese (cn.2firsts.com), and Spanish (www.2firsts.com/es) websites. 2FIRSTS global reporting team is distributed across Shenzhen, Hong Kong, Europe and the United States.

 

2FIRSTS maintains open and trusted communication with regulators, industry leaders, associations, media, etc. As a pioneering value service provider in the global tobacco and NGP industry chain, 2FIRSTS is committed to promoting NGP technological innovation, compliance development, and the fulfillment of social responsibility. It aims to achieve high-quality development of the global NGP industry and bring a more harm-reducing and safe lifestyle to tobacco consumers worldwide.

 

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28